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Advancing hepatitis B virus entry inhibitors
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Despite the effective antivirals and vaccines, chronic hepatitis B virus (HBV) infection 
remains a major public health problem worldwide [1,2]. Due to limited access, late or absent 
detection and vertical transmission, the prevalence of HBV infection is estimated to be 250–
350 million infected individuals [1,3]. HBV infection is a leading cause of hepatocellular 
carcinoma worldwide. While current therapies, based on pegylated-interferon and 
nucleos(t)ide analogs effectively decrease viral load, viral elimination is rare. Thus, there is 
an unmet medical need for novel therapeutic strategies effectively curing HBV infection 
[1,2,4]. HBV entry inhibitors have been introduced as a novel class of antivirals for viral 
control and cure [1,5–7]. The discovery of the Na+-taurocholate cotransporting polypeptide 
(NTCP) as the first receptor of HBV opened the door to understand the molecular 
mechanisms of viral cell entry and to identify entry inhibitors (reviewed in [8]). In the liver, 
HBV virions bind to NTCP, a bile acid transporter expressed at the basolateral membrane of 
hepatocytes [9], triggering viral entry. The preS1 region of HBV envelope interacts with the 
bile acid pocket site of the transporter, corresponding to the amino acids 157 to 165 of the 
protein [8], therefore interfering with its transporter function. At the same time NTCP has 
been explored in great detail as a target for antiviral therapy (reviewed in [5]). Indeed, small 
molecules interacting with NTCP exhibit antiviral activity, including the immunosuppressive 
drug cyclosporin A (CsA) [5]. Moreover, a preS1 peptide derived from the HBV envelope 
and specifically binding to the receptor has been shown to exhibit marked antiviral activity 
in cell culture, animal models and patients (for reviews, see [5,6]). However, as HBV and 
bile acids share the same interaction site with NTCP, the current HBV NTCP entry inhibitors 
are also capable of interfering with bile acid uptake. This may induce putative adverse 
effects by impairing Na+-taurocholate transport in hepatocytes. Indeed NTCP deficiency in 
patients leads to hypercholanemia for instance [10] and an increase in glycine-conjugated 
bile acid concentrations was also observed in some patients treated with myrcludex B, a 
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preS1 peptide binding to NTCP and currently evaluated in a clinical trial [11]. Although bile 
acid related adverse effects appeared to be limited or absent [11], the discovery of HBV 
entry inhibitors not affecting the NTCP transporter function would represent an interesting 
conceptual advancement addressing a potential safety concern.
In this issue of Journal of Hepatology, Shimura and colleagues [19] addressed this issue, by 
investigating the ability of CsA derivatives to inhibit HBV infection without interfering with 
bile acid transport. To do so, they took advantage of an HBV infection model based on 
NTCP-overexpressing HepG2 cells, named HepG2-hNTCP-C4, which enables HBV 
infection [12]. The authors synthesized eleven CsA derivatives and characterized their 
inhibitory activity on virus infection. Observing that five of these drugs were able to inhibit 
HBV infection in a pan-genotypic manner, they demonstrated that four of them (named 
SCY806, SCY446, SCY450, and SCY995) have no immunosuppressive activity and were 
capable of suppressing HBV infection in primary human hepatocytes (PHH). To further 
characterize the antiviral activity of these compounds, they then tested their inhibitory effect 
at different stages of viral infection. Using non-susceptible HBV replicating cells, they 
demonstrated that CsA derivatives had no effect on HBV replication. In contrast, taking 
advantage of a fluorescent-labeled preS1 peptide, which specifically binds to NTCP [13], the 
authors showed that these drugs were able to prevent preS1-NTCP interaction, confirming 
the capacity of CsA derivatives to inhibit HBV entry by interfering with the binding of the 
virus to its receptor. They validated these findings using surface plasmon resonance analysis, 
showing that CsA derivatives were capable of interacting with recombinant NTCP protein, 
such as CsA itself. As CsA is known to target NTCP-mediated bile acid uptake as well, the 
authors set up a bile acid uptake assay based on HepG2-hNTCP-C4 cells to evaluate the 
putative effect of CsA derivatives on NTCP transporter function. Interestingly, while 
SCY806 and SCY446 do inhibit bile acid uptake similarly to CsA, the two other derivatives, 
SCY450 and SCY995, had no effect on NTCP-mediated bile acid transport in spite of a 
strong HBV inhibition, suggesting that the bile acid transporter and HBV receptor functions 
of NTCP can potentially be dissociated. This hypothesis was further confirmed by 
sulfobromophthalein, a substrate of NTCP interacting with the bile acid pocket site of the 
protein [14], which was shown to inhibit bile acid uptake without affecting HBV infection. 
Taken together, the authors conclude that it is possible to develop NTCP-targeting HBV 
entry inhibitors without affecting the bile acid transporter function of NTCP.
These results have implications for the understanding of HBV entry as well as the 
development of HBV entry inhibitors as antivirals. First, the results obtained by Shimiura et 
al. suggest that NTCP domains mediating HBV entry and bile acid transport may not be 
completely identical. The newly identified compounds could serve as a tool to further 
elucidate virus-NTCP interactions during HBV cell entry. Furthermore, their findings could 
advance the further development of HBV entry inhibitors: while host-targeting agents 
(HTAs) have been shown to be effective against HBV, HDV and HCV infections [7,15,16], 
target-specific adverse effects need to be carefully addressed [17]. Although it has been 
suggested that auxiliary transporters may be able to sustain the enterohepatic cycle in the 
absence of NTCP [10], it cannot be excluded that pharmacological long-term modulation of 
bile acid transport may result in previously undiscovered adverse effects. Shimura and 
colleagues addressed this issue by the identification of CsA derivatives which neither 
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appeared to exhibit immunosuppressive activity, nor interfer with NTCP-mediated bile acid 
transport. Mechanistically, their study suggests that the SCY995 molecule may target an 
alternative site of NTCP (putatively overlapping with the bile acid pocket site) compared to 
native CsA, which may allow to inhibit viral entry without blocking bile acid uptake (Fig. 
1). However, it is important to note while no effect was observed in the range of 
concentrations used in the study, it cannot be excluded that SCY995 interferes with NTCP 
bile acid transporter function at higher concentrations. Furthermore it would be of interest to 
investigate whether SCY995 interferes with the recently described antiviral innate immune 
responses mediated by the NTCP bile acid transporter function [18]. Collectively, the 
findings of Shimura et al. advance our knowledge by showing: (i) that it appears to be 
possible to dissect HBV entry and bile acid transporter function; and (ii) providing an 
opportunity to optimize entry inhibitors by potentially increasing their specificity and 
decreasing potential adverse effects. However, it would be important to assess whether the 
compounds exhibit other off-target effects such as interference with other transporters (e.g. 
the hepatic organic anion transporting polypeptide OATP). Detailed studies of efficacy and 
safety in animal models and ultimately in the HBV infected patients are needed to evaluate 
the positioning of the approach introduced by Shimura and colleagues compared to the entry 
inhibitor myrcludex B [11], other HTAs (for review see [7]) and clinically licensed HBV 
antivirals.
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Fig. 1. Model of interaction of selected HBV entry inhibitors and Na+-taurocholate 
cotransporting polypeptide (NCTP) at the hepatocyte basolateral membrane
According to Shimura and colleagues, CSY995, a CsA derivative exhibiting no 
immunosuppressive activity, contrary to CsA, appears to bind to NTCP via an alternative site 
(putatively overlapping with the bile acid pocket site of the protein), allowing bile acid 
transport in spite of a strong anti-HBV activity. Myrcludex B (MyrB) is a myristoylated 
peptide derived from the HBV envelope specifically binding to NTCP, inhibiting both HBV 
entry and bile acid transport. CsA, cyclosporine A; HBV, hepatitis B virus.
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